

09PH
V626



GM-CSF protection of CML CD34⁺ cells from the inhibitory effect of imatinib

Pongtep Viboonjuntra

Melissa White Leukaemia Research Laboratory
Division of Haematology
Institute of Medical & Veterinary Science
And
Hanson Institute

&

Department of Medicine
The University of Adelaide
South Australia

A thesis submitted to the University of Adelaide
in candidature of the degree of Doctor of Philosophy
February 2006

ABSTRACT

Imatinib mesylate has become the front line therapy for CML. It inhibits the ABL tyrosine kinase activity of the causative oncogenic fusion protein BCR/ABL. The efficacy of imatinib therapy has been impressive, with a majority of patients achieving complete cytogenetic responses. However, to date imatinib therapy has been unable to completely eradicate the leukaemic clone in the majority of cases. This suggests that leukaemic stem cells may not be totally dependent on the activity of BCR/ABL, or that there may be other factors supporting the survival of leukaemic cells. Cytokines of the IL-3 family are involved in the survival and growth of myeloid haemopoietic cells. A number of the signals generated are in common with the pathways used by BCR/ABL and previous published studies showed that the IL-3 family member GM-CSF was found in elevated levels in CML patient serum. Therefore, the central aim was to test whether GM-CSF could modulate the response of CML progenitors to imatinib. In addition, a further aim was to examine CML cell production of GM-CSF. When CML CD34+ cells were exposed to imatinib, spontaneous BCR/ABL driven cell division was strongly inhibited, and cells became apoptotic. However, the addition of GM-CSF reversed this effect, returning cell division and survival back to spontaneous levels. GM-CSF specificity was confirmed using the antagonist E21R. The cell division and survival of leukaemic CD34+ cells in cultures of total CML mononuclear cells were less sensitive to imatinib inhibition. However, inclusion of E21R in such cultures resulted in a similar pattern to CD34+ CML cells cultured alone. This suggested that non-CD34+ cells may be a source of GM-CSF. This was confirmed by sorting CD34+ and non-CD34+ CML cells and examining GM-CSF production, which was markedly more apparent in the non-CD34+ compartment. Finally, the effects of GM-CSF on the survival and proliferation pathways induced by BCR/ABL were examined, showing it may exert its effects through p-Erk and p-Akt mediated mechanisms. Our data suggest that GM-CSF can signal via pathways which are normally suppressed due to alternative activation of major substrates by BCR/ABL, as well as others which are not activated by BCR/ABL, leading to cell survival when kinase activity is blocked by imatinib.

TABLE OF CONTENTS

DECLARATION.....	I
ACKNOWLEDGEMENTS	II
ABSTRACT.....	VI
ABBREVIATIONS.....	VII
PRESENTATIONS AND PUBLICATIONS.....	XII
CHAPTER 1: GENERAL INTRODUCTION	
1.1. PREFACE.....	1
1.2. HISTORY OF CHRONIC MYELOID LEUKEMIA.....	1
1.3. CLINICAL OVERVIEW AND THERAPY OF CHRONIC MYELOID LEUKEMIA.....	2
1.3.1. Epidemiology.....	2
1.3.2. History of CML treatment.....	3
1.3.2.1. Busulfan and Hydroxyurea	3
1.3.2.2. Interferon- α	4
1.3.2.3. Chemotherapy and bone marrow transplantation.....	5
1.3.2.4. The tyrosine kinase inhibitor imatinib.....	5
1.4. Molecular pathophysiology of CML.....	6
1.4.1. Normal p145 protein.....	7
1.4.2. Normal BCR protein.....	10
1.4.3. More studies on the function of normal BCR and ABL.....	11
1.4.4. The BCR/ABL fusion protein or p210 ^{BCR/ABL} protein.....	13
1.5. Cellular signaling pathways relating to the BCR/ABL protein.....	15
1.5.1. Ras pathways.....	16
1.5.2. PI3-K pathway	17
1.5.3. C-Cbl and Crkl pathways	19
1.5.4. Myc pathway.....	20
1.5.5. Jak/STAT.....	20
1.6. Haemopoietic cytokines of the IL-3 family involved in signaling through BCR/ABL.....	21
1.6.1. IL-3 receptor super family.....	22
1.6.2. GM-CSF and its receptor.....	24
1.6.3. The importance of cytokine and cytokine receptors in haematopoietic	

disease and neoplasia.....	25
1.7. Proposed studies in this thesis.....	27
1.7.1. Cell growth driven by BCR/ABL is cytokine dependent.....	27
1.7.2. Imatinib therapy of CML is not curative.....	28
1.7.3. GM-CSF may maintain survival of CML progenitors and help CML progenitors to escape eradication by imatinib.....	29
1.8. Hypothesis and aims of the thesis.....	31
1.9. Summary.....	32

CHAPTER 2: MATERIALS AND METHODS

2.1. Suppliers of commonly used reagents.....	33
2.2. Buffers and Solutions used un cell culture.....	36
2.3. Cell Culture Techniques.....	44
2.3.1. Maintenance of cell lines.....	44
2.3.1.1. Cryopreservation of cell lines.....	44
2.3.1.2. Thawing cell lines.....	44
2.3.1.3. Performing the cell culture.....	45
2.3.2. Maintenance of primary CML cells.....	46
2.3.2.1. Ficolling technique for primary CML cells.....	46
2.3.2.2. Cryopreservation of primary CML cells.....	46
2.3.2.3. Thawing the primary CML cells.....	46
2.3.2.4. Performing CML cell culture.....	47
2.4. General cell washing.....	47
2.5. General cell number and viability assessment.....	48
2.6. Immunofluorescence and flow cytometry.....	48
2.7. Haematopoietic colony assays.....	50
2.8. Protein analysis	53
2.8.1. Molecular Biology reagents.....	53
2.8.2. Method of Western immunoblot.....	57
2.9. Statistical methods.....	59

CHAPTER 3: THE RESPONSE OF CML CD34⁺ CELLS TO GM-CSF

3.1. Introduction.....	60
3.2. Aims of the study.....	63
3.3. Special methods.....	63
3.3.1. Dye dilution technique (CFSE).....	63
3.3.1.1. Non-division related decrease in CFSE intensity.....	64
3.3.1.2. Calculation of proliferation index.....	65
3.4. Results.....	66

3.4.1.	Titration of GM-CSF study.....	66
3.4.2.	Comparison of proliferation between normal and CML CD34 ⁺ cells.....	67
3.4.3.	GM-CSF enhances the proliferation of CML CD34 ⁺ cells.....	68
3.4.4.	The response of CML CD34 ⁺ cells to GM-CSF, IL-3 and G-CSF.....	68
3.5.	Discussion.....	69

CHAPTER 4: MODULATION OF IMATINIB EFFECT ON CML CD34⁺ CELLS BY GM-CSF

4.1.	Introduction.....	73
4.2.	Aims of the study.....	76
4.3.	Special methods.....	76
4.3.1.	Colorimetric MTS assays.....	76
4.4.	Statistical methods.....	77
4.5.	Results.....	77
4.5.1.	A time-course experiment to evaluate cell proliferation by CFSE.....	77
4.5.2.	GM-CSF could reverse spontaneous growth of CML CD34 ⁺ cells with imatinib.....	77
4.5.3.	GM-CSF prevents imatinib suppression of proliferation of CML CD34 ⁺ cells.....	79
4.5.4.	GM-CSF could improve viability of CML CD34 ⁺ cells.....	80
4.5.5.	MTS assay to evaluate cell survival in cultures with imatinib, GM-CSF and E21R.....	81
4.5.6.	Percent viability of parent cells using dye dilution method.....	81
4.5.7.	GM-CSF titration to confirm that the signals activated by BCR/ABL could be replaced by added GM-CSF in the presence of imatinib.....	83
4.5.8.	Colony assay evaluating the progenitor survival after 3 days of fluid culture.....	84
4.6.	Discussion.....	84

CHAPTER 5: EFFECT OF BYSTANDER CELLS ON CML CD34⁺ CELL BEHAVIOUR

5.1.	Introduction.....	88
5.2.	Aims of the study.....	89
5.3.	Special methods.....	89
5.3.1.	MTS assay to compare between the survival of CML CD34 ⁺ cells and mixed mononuclear cells in the conditioned culture.....	89
5.3.2.	Evaluation of the bystander effect.....	90
5.3.3.	ELISpot method to detect GM-CSF production of CML cells.....	92
5.3.3.1.	Preparation of ELISpot plate.....	92

5.3.3.2.	Incubation of cells in the plates.....	92
5.3.3.3.	Detection of GM-CSF production.....	92
5.4.	Results.....	93
5.4.1.	Comparison of cell survival between CML CD34 ⁺ cells in CML CD34 ⁺ cell only and in mixed mononuclear culture.....	93
5.4.2.	CML CD34 ⁺ cells underwent more proliferation in mixed mononuclear culture.....	94
5.4.3.	Non CD34 ⁺ CML cells induce cell proliferation and improve viability of CML CD34 ⁺ cells.....	95
5.4.4.	The effect of bystander helps to maintain cell survival rather than cell proliferation.....	96
5.4.5.	GM-CSF is predominantly produced by non-CD34 ⁺ CML cells.....	97
5.5.	Discussion.....	97

CHAPTER 6: MECHANISM OF PROTECTION FROM IMATINIB BY GM-CSF

6.1.	Introduction.....	102
6.1.1.	Overview from the previous Chapter.....	102
6.1.2.	Role of normal c-ABL.....	102
6.1.3.	Mechanism of c-ABL shuttling between nucleus and cytoplasm.....	103
6.1.4.	Regulation of cell apoptosis.....	104
6.1.5.	Role of Bim.....	105
6.2.	Aims of the study.....	106
6.3.	Special methods.....	107
6.3.1.	MTS assay to evaluate bio-kinetic activity of cell lines.....	107
6.3.2.	Western immunoblot method.....	108
6.3.2.1.	Western immunoblot with total cell lysate.....	108
6.3.2.2.	Western immunoblot with immunoprecipitated sample.....	108
6.4.	Results.....	109
6.4.1.	Wt-BCR-ABL/ CTLEN cells in culture with titrated GM-CSF by MTS assay.....	109
6.4.2.	MTS assay to evaluate different cell lines.....	110
6.4.3.	MTS assay to evaluate the wt-BCR-ABL / CTLEN with the titrated imatinib.....	110
6.4.4.	Mechanism of GM-CSF to protect cells from imatinib.....	111
6.4.4.1.	Evaluation of p-Akt in total cell lysate.....	111
6.4.4.2.	Bim expression in total cell lysate.....	112
6.4.4.3.	Evaluation of p-Crkl.....	113
6.4.4.4.	Evaluation of p-Erk.....	113
6.4.4.5.	Immunoprecipitation of Akt.....	113
6.4.4.6.	Immunoprecipitation of Bim.....	114
6.4.4.7.	Bad distribution in wt-BCR-ABL/ CTLEN with conditioned Culture.....	115
6.5.	Discussion.....	116

CHAPTER 7: GM-CSF AND APOPTOSIS OF PRIMARY CML CD34⁺ CELLS

7.1. Introduction.....	124
7.2. Aims of the study.....	125
7.3. Special methods.....	125
7.3.1. Examination of active caspase expression by FLICA method.....	125
7.4. Results.....	126
7.4.1. Study of the proliferation of CML CD34 ⁺ cells and bystander effect in one patient.....	126
7.4.2. Comparison of p-Akt in both primary CML CD34 ⁺ cells and cell line wt-BCR-ABL / CTLEN.....	127
7.4.3. Evaluation of p-Erk.....	128
7.4.4. Upregulation of the apoptotic regulatory protein Bim by imatinib.....	128
7.4.5. The total caspase activation in CML CD34 ⁺ cells in CML CD34 ⁺ only culture and in mixed mononuclear culture.....	130
7.4.6. Apoptotic index.....	131
7.5. Discussion.....	132
CHAPTER 8: GENERAL DISCUSSION.....	137
CHAPTER 9: REFERENCES.....	149